Immune Checkpoint Therapeutics – Hot Targets & Pipeline Analysis

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Immune Checkpoints Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future Immune Checkpoint treatment space. The report in addition to the monotherapy covers the pipeline for combination therapies associated only with checkpoint agents.

In order to effectively deal various diseases, the immune system needs to be able to generate an appropriate counter response. However, as a part of the natural fail–safe mechanism, to limit overactive immune responses that could lead to an auto-immune disease, there are a number of markers (“immune checkpoint receptors”) found on both tumor cells and antigen presenting cells (dendritic cells, macrophages etc.) that can down-regulate or suppress T cells once the corresponding ligand is bound.

Currently, Researchers are challenged to identify various avenues to prevent T cells from binding these tolerance-inducing ligands either through antibodies or recombinant forms of ligand or receptors. So, these T cells remain active and ready to tackle various diseases. Owing to its high response rate and prolonged overall patient survival the checkpoint therapeutics are gaining in popularity and have shown some impressive results in the areas of Oncology, Inflammation, Respiratory, Autoimmune and Infectious disease. 

Key Findings:

• The global Immune Checkpoint therapeutics market is estimated to be $XX billion in 2015 with the approval of new drugs and is expected to grow at a CAGR of high-range double digit from 2016 to 2022 to reach $40.8 billion by 2022.
• Factors contributing to the market growth include, Launch of approved drugs, technological advancements leading to emergence of novel therapeutics & mechanisms, increase in investments, increasing incidence of cancers and low survival rates .
• IQ4I analysis indicates that 31.7% of candidates are in Pre-clinical stage followed by xx% in PI clinical
• In addition to small molecules, there is growing interest among researchers on large molecules and novel therapies, such as

• Monoclonal antibody-based therapy
• Recombinant proteins
• Bi-specific Ab’s
• Antibody drug conjugates
• Cell therapy
• Peptides
• Oncolytic viruses
• Vaccines

Pipeline Analysis

Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule. Covers both Monotherapy and Combinations

• Pipeline analysis by developmental stage (Discovery to Clinical development)
• Pipeline analysis by modalities
  • Monoclonal antibody-based therapy
  • Recombinant proteins
  • Bi-specific Ab’s
  • Antibody drug conjugates
  • Cell therapy
  • Peptides
  • Oncolytic viruses and
  • Vaccines
• Pipeline analysis by leading players & Target analysis
• Drug analysis based on mechanism.